FDA approves IV immunoglobulin therapy for CIDP in adults

The FDA has approved Gammagard Liquid as an IV immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy.
According to a release from Takeda, approval for Gammagard Liquid (immune globulin infusion [human] 10% solution) was based on results from ADVANCE-CIDP 2, a prospective, open-label, single-arm, multicenter clinical study that evaluated safety and efficacy in adults with CIDP who developed a relapse in the ADVANCE-CIDP 1 study, a randomized, double-blind, placebo-controlled study evaluating safety, efficacy

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart